chronic kidney disease

Pharma

FDA safety probe, Otsuka, ADC patent fight—Fierce Pharma Asia

Takeda's Adzynma is under an FDA safety probe. Otsuka snagged a first-in-class FDA approval in IgAN. Daiichi one-ups Pfizer in their ADC patent fight.

Angus Liu Dec 5, 2025 8:45am

Otsuka wins FDA nod in ever-more-crowded kidney disease space

Nov 26, 2025 11:10am

Akebia drops Vafseo trial, failing to get 'alignment' with FDA

Oct 29, 2025 11:31am

Fierce Biotech

Novo vs. KBP Chapter 4: Lessons from the $1.3B fallout

Oct 2, 2025 3:00am

FDA approves Corstasis' nasal spray as treatment for edema

Sep 15, 2025 3:33pm

Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia

Aug 29, 2025 8:15am